Viking Therapeutics: Investor Attention Turns to Clinical Pipeline Updates

Investor focus returns to Viking Therapeutics next week as company executives prepare to outline their strategic vision at two major industry events in Miami. These appearances offer the market a timely opportunity to gain fresh insights into the progression of the firm’s pivotal obesity treatment program.

Dual Conference Appearances Scheduled

The company’s leadership team has a packed schedule. Viking will participate in the Leerink Partners Global Healthcare Conference 2026, running from March 8 to March 11. A key “Fireside Chat” presentation is slated for 10:40 a.m. Eastern Time on Tuesday, March 10.

Concurrently, management will also attend the Jefferies Biotech on the Beach Summit, which takes place on March 10 and 11. Beyond the public presentations, these forums are primarily used by the company to facilitate private, one-on-one discussions with institutional investors.

Should investors sell immediately? Or is it worth buying Viking Therapeutics?

Spotlight on Lead Candidate VK2735

The central topic for investors will be the development of VK2735. This dual GLP-1 and GIP receptor agonist is the cornerstone of Viking’s pipeline targeting metabolic diseases. The injectable formulation is already advancing through the Phase 3 “VANQUISH” clinical program.

However, market observers are likely to pay particular attention to plans for an oral version of the drug. Viking Therapeutics intends to initiate a Phase 3 trial for the tablet formulation in the third quarter of 2026. In a sector where valuations are heavily influenced by clinical milestones, any updates to this development timeline are crucial for assessing the equity’s prospects.

Interested parties can evaluate the latest commentary on commercialization strategy directly by accessing a live webcast of the March 10 presentation through the company’s website.